UPDATE on URINARY INCONTINENCE

New Developments That are Changing Patient Care

Promising therapies: TOT, duloxetine, botulinum A

Associate Professor
University of Pittsburgh School of Medicine
Magee-Women’s Hospital
Department of Obstetrics, Gynecology, and Reproductive Sciences

Ob/Gyns are being called on more than ever to initiate treatment for urinary incontinence, and new treatment options are enabling us to play a more active role than ever before in treating one of the most common and distressing of chronic diseases in women. Urinary incontinence affects women after menopause, primarily. Prevalence increases (though not in a linear fashion)—from 20% to 30% in reproductive-aged women, to 30% to 40% in postmenopausal women. Approximately 16 million Americans are affected, and the number of women affected is more than double that of men.